Loading…
Loading…
what gives you confidence in a second-half launch? Does that assume priority review for FDA
I wonder if you could give us a little more detail to how much of the lives have prior auths or co-pay or any other restrictions
the process to add lenacapavir to the USPSTF mandate for coverage about cost sharing
if you could give us your reflections on the competitiveness of the late-stage oncology portfolio
I wonder if you could update us on your biomarker strategy. Given a TROP-two ADC competitor
an update on KEYTRUDA and the proportion of the sales that you have from early-stage settings
What's your bar for success on both of those? And if you replicate those outcomes in Phase III
Can you help us understand what outcomes you may be able to provide from that trial given the enrollment